Myelodysplastic Syndrome Clinical Trial

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Summary

The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

View Eligibility Criteria

Eligibility Criteria

Eligible patients must have a diagnosis of myelodysplastic syndrome
Life expectancy of at least 6 months.
Patients must be able to adhere to the study visit schedule and other protocol requirements.
Patients must understand and voluntarily sign an informed consent document.
Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment.
Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

220

Study ID:

NCT00050843

Recruitment Status:

Completed

Sponsor:

Celgene Corporation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 38 Locations for this study

See Locations Near You

Scripps Cancer Center
La Jolla California, 93037, United States
Comprehensive Cancer Centers of the Desert
Palm Springs California, 92262, United States
Desert Hematology Oncology Medical Group INC
Rancho Mirage California, 92270, United States
Whittingham Cancer Center
Norwalk Connecticut, 06856, United States
VA Connecticut Healthcare System
West Haven Connecticut, 06516, United States
Florida Cancer Specialists
Fort Myers Florida, 33901, United States
Southeast Florida Hematology-Oncology
Ft. Lauderdale Florida, 33308, United States
Northwest Medical Specialists
Arlington Heights Illinois, 60004, United States
Oncology Associates
Cedar Rapids Iowa, 52403, United States
Beaumont Cancer Center
Royal Oak Michigan, 48073, United States
SMDC Health Systems
Duluth Minnesota, 55805, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Jackson Oncology Associates PLLC
Jackson Mississippi, 39202, United States
Hematology Oncology Consultants Inc
St. Louis Missouri, 63136, United States
Southern Nevada Cancer Research Foundation
Las Vegas Nevada, 89106, United States
Hematology Oncology Associates of NJ
Paramus New Jersey, 07652, United States
Summit Medical Group/Overlook Oncology Center
Summit New Jersey, 07901, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
Memorial Sloan Kettering Cancer Ctr
New York New York, 10021, United States
VAMC Northport
Northport New York, 11768, United States
University of Rochester Cancer Center
Rochester New York, 14642, United States
South Shore Hem-Onc Assoc. PA
Rockville Centre New York, 11570, United States
Staten Island Unversity Hospital
Staten Island New York, 10305, United States
Westchester County Medical Center
Valhalla New York, 10595, United States
Buffalo Medical Group PC
Williamsville New York, 14221, United States
Northwestern Carolina Hematology Oncology PA
Hickory North Carolina, 28602, United States
Wake Forest Univ School of Medicine
Winston Salem North Carolina, 27157, United States
Oncology/Hematology Care Inc
Cincinnati Ohio, 45246, United States
Oregon Health & Science University
Portland Oregon, 97201, United States
Medical Oncology Associates
Kingston Pennsylvania, 18704, United States
Lancaster Cancer Center LTD
Lancaster Pennsylvania, 17605, United States
MCP Hahnemann University
Philadelphia Pennsylvania, 19129, United States
Western Pennsylvania Cancer Institute
Pittsburgh Pennsylvania, 15224, United States
Texas Oncology PA-BMT Center
Dallas Texas, 75230, United States
Central Utah Medical Clinic
Provo Utah, 84604, United States
InterMountain Hematology/Oncology
Salt Lake City Utah, 84122, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
Yakima Regional CancerCenter
Yakima Washington, 98902, United States

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

220

Study ID:

NCT00050843

Recruitment Status:

Completed

Sponsor:


Celgene Corporation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider